Treatment availability and patient outcomes are critical issues for the pharmaceutical industry, particularly in eye care. Patients do not always respond favorably to established medications and other therapeutic options. Eye drops, the most commonly administered agent, possess a bioavailability of under six percent. This means that the vast majority of the solution fails to hit its target because of factors like your eye’s natural defenses and tear washout.
There are fewer successful treatment outcomes when combining issues like these with associated discomforts and inconveniences associated with administration. Ojas Doshi employs a straightforward approach to combat these difficulties: developing delivery systems that improve such therapies.
Ojas Doshi
Making Treatment Advancements
Doshi demonstrates a can-do mentality, focusing on the creation of therapeutic regimens capable of meeting a patient’s needs rather than forcing you to adapt to tired, antiquated methods. He addresses existing problems and seeks immediate solutions regarding patient care and how healthcare companies should approach these matters.
As aging persons encounter growing rates of various eye-related maladies, the need to make strides regarding drug delivery carries greater urgency. It is a life-long goal that Doshi intends to attain.
Displaying Notable Foresight
Doshi takes pharmaceutical science to another level. He emphasizes that drug delivery methods go beyond formulations and must also consider other key topics, including the importance of treating patients like people rather than merely test subjects and making sure that they get the most out of their treatment with the least amount of difficulty.
As the product development scientist at Cosette Pharmaceuticals, Inc., he applies his knowledge of new drug applications (NDA) and abbreviated new drug applications (ANDA) to therapeutics such as topical creams, oral preparations, and sterile dosage forms. His most noteworthy contributions are in eye care-related drug delivery and oral solutions.
His undying attention to improved patient care outcomes has led to Doshi creating variations of eye infection-combating drugs like tobramycin and moxifloxacin. Such preparations strengthen each drug’s potency, are simpler to administer, and do not need to be taken as often. They have also improved patient adherence by shortening recovery times and lessening associated medical costs.
“Innovation is bridging the gap between pharmaceutical discovery and practical, patient-friendly solutions,” Doshi said.
Ojas Doshi
A Growing List of Satisfied Patients
Doshi is currently working with five patients dealing with eye disease or damage. However, his work is expanding beyond eye care. The renowned scientist holds a provisional patent recently filed for a new liquid medication addressing the bothersome condition of dry mouth. This effort could become an accepted alternative to existing pill-based therapies.
Final Thoughts
Doshi’s work in the eye care discipline is positioned to precipitate a lingering and positive influence on an international scale. His efforts in producing treatments that reduce costs and improve patient outcomes inspire healthcare companies worldwide to develop therapeutic regimens possessing similar attributes.
With a growing patient list and the desire to formulate unique treatment forms, Doshi sees a future where all drug delivery systems are patient-centered, promising a better and smoother operating healthcare field.
